Translating Hope to Help™

Phage Refinery helps businesses commercialize biologic alternatives to the bacterial “superbug” pathogens that chemical medicines can no longer contain.

Learn More

Your Partner for Commercial Success

By making the results of over 40 years of innovative bacteriophage research readily available to biotech companies developing phage-powered products, Phage Refinery helps you maximize value, performance, and impact. We succeed when you succeed.

Focused Value, Broad Application

Bacteriophages have a wide variety of applications including but not limited to:

Human Health

Enhancing potential phage therapy candidates and helping fight drug-resistant infections in hospitals.

Agriculture

Combating bacterial infections in plants and livestock.

Industrial

Mitigating pathogens in HVAC units, treatment facilities, extraction/pumping systems, and other industrial applications.

Defense

Biodefense both at home and abroad and resisting exotic battlefield infections.

The Leading Platform for Refining Phages

Our innovative phage refining platform offers multiple entry points to best fit your needs. Purity, aggression, persistence and stability can all be improved by our proprietary technologies.

Characterization

Baseline key physical parameters that strongly influence a phage’s performance and viability.

Aggression Enhancement

Proprietary methods can deliver “hyper-aggressive” phages with orders-of-magnitude increase in virility.

Persistence Enhancement

Sufficient phage persistence in the presence of host immune response is critical to its effectiveness.

Purification

Novel biochemical treatments virtually eliminate host and endotoxin contaminants.

Stabilization

Austere environments such battlefields and disaster areas demand long-term stability and ease of transport.

Founding Team

Philip Serwer, PhD

Founder, Chief Science Officer

Life-long bacteriophage researcher. Professor of Biochemistry and Structural Biology, UT Health Science Center San Antonio.

James Chambers, PhD

Co-founder, EVP R&D

Principal scientist behind the viral transport safety reagent that is the standard for COVID-19 PCR tests. Professor of Microbiology, University of Texas at San Antonio.

William A. (Bill) Tolhurst

Co-founder, CEO

Serial Entrepreneur in wireless, location services, SaaS, IoT and renewable energy.

Advisory Board

James J. Bull, PhD

Chair, Scientific Advisory Group

Seminal work in phage genetics, evolution. Professor, University of Idaho. Member of the National Academy of Sciences and the American Association for the Advancement of Science.

Mike Sember

Chair, Business Advisory Group

40-year career in the pharmaceutical industry. Multiple CxO roles, R&D, Sales, M&A. Screening Panel, Desert Angels.

A. Andrew Jones, PhD

Member, Science Advisory Group

Dr. Jones' research uses engineering and policy analysis to help solve global challenges related to water and health. Holds a BS in Mathematics and BS, MS, and PhD in Mechanical Engineering from MIT. Associate Professor, Duke University.

Patrick C. Ng, MD

Member, Science Advisory Group

Director, Emergency Medicine Research Air Force Trauma Physician. Air Force 59th Medical Wing ER Physician, University Hospital.

Gilad Odinak

Member, Business Advisory Group

Microsoft Research, Avaya. 200+ issued patents. Founder of a SaaS firm acquired for 9-figures. Extensive AI expertise.

Dwayne Roach, PhD

Member, Science Advisory Group

Director/PI, Roach Phage Lab. Phage PK/PD. Phage manufacturing technologies. Associate Professor, San Diego State University.

Affiliates and Collaborators

We know that a company’s success depends strongly on having great relationships with like-minded members of our community, industry, and the larger business ecosystem. So we’re proud to highlight these organizations that have been so helpful in both getting us where we are and where we’re headed.

Become a Partner

Investors

As a growing company, Phage Refinery is always excited to speak with well-qualified investors that are keen to join us on our journey. Just click on the button below to let us know you’re interested, and we’ll be happy to talk more about the opportunity.

Investor Inquiry